Litcius/Paper detail

Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma

Ananth Shankar, Tom Kurzawinski, Emma Ross, Sara Stoneham, Tim Beale, Ian Proctor, Tony Hulse, Kate Simpson, Mark N. Gaze, Elene Cattaneo, Evelien Gevers, Lynley V. Marshall, Johnathan Hubbard, Caroline Brain

2021European Journal of Cancer19 citationsDOI

Topics & Concepts

MedicineMultiple endocrine neoplasia type 2CalcitoninThyroid carcinomaCarcinoembryonic antigenInternal medicineGastroenterologyContext (archaeology)Medullary thyroid cancerAdverse effectProgressive diseaseOncologyThyroidEndocrinologyDiseaseCancerGermline mutationMutationBiochemistryPaleontologyChemistryBiologyGeneThyroid Cancer Diagnosis and TreatmentNeuroendocrine Tumor Research AdvancesThyroid and Parathyroid Surgery
Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma | Litcius